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Abstract
Background: Despite intensive insulin treatment, many patients with type-1 diabetes (T1DM) have longstanding
inadequate glycaemic control. Metformin is an oral hypoglycaemic agent that improves insulin action in patients with type-
2 diabetes. We investigated the effect of a one-year treatment with metformin versus placebo in patients with T1DM and
persistent poor glycaemic control.
Methodology/Principal Findings: One hundred patients with T1DM, preserved hypoglycaemic awareness and
HaemoglobinA1c (HbA1c) $8.5% during the year before enrolment entered a one-month run-in on placebo treatment.
Thereafter, patients were randomized (baseline) to treatment with either metformin (1 g twice daily) or placebo for
12 months (double-masked). Patients continued ongoing insulin therapy and their usual outpatient clinical care. The
primary outcome measure was change in HbA1c after one year of treatment. At enrolment, mean (standard deviation)
HbA1c was 9.48% (0.99) for the metformin group (n=49) and 9.60% (0.86) for the placebo group (n=51). Mean (95%
confidence interval) baseline-adjusted differences after 12 months with metformin (n=48) versus placebo (n=50) were:
HbA1c, 0.13% (20.19; 0.44), p=0.422; Total daily insulin dose, 25.7 U/day (28.6; 22.9), p,0.001; body weight, 21.74 kg
(23.32; 20.17), p=0.030. Minor and overall major hypoglycaemia was not significantly different between treatments.
Treatments were well tolerated.
Conclusions/Significance: In patients with poorly controlled T1DM, adjunct metformin therapy did not provide any
improvement of glycaemic control after one year. Nevertheless, adjunct metformin treatment was associated with
sustained reductions of insulin dose and body weight. Further investigations into the potential cardiovascular-protective
effects of metformin therapy in patients with T1DM are warranted.
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Introduction
Despite intensive insulin treatment and patient care, many
patients with type-1 diabetes have longstanding poor metabolic
control and their glycaemic levels remain substantially higher than
the recommended target of HaemoglobinA1c (HbA1c) less than
7.0% [1,2]. As recently reviewed by deVries et al., the
phenomenon of persistent poor glycaemic control seems to have
multiple and complex causes and, so far, no simple, single solution
to this problem has emerged [2]. The Diabetes Control and
Complication Trial demonstrated the beneficial effect of improv-
ing glycaemic control on the long-term risk of late-diabetic
complications [3,4]. Decreased muscle glucose uptake in response
to insulin (i.e., decreased insulin action, otherwise known as
‘‘insulin resistance’’) has been demonstrated in patients with type-1
diabetes [5] and this might contribute to the development and
maintenance of their poor glycaemic control.
Metformin is an oral anti-hyperglycaemic agent that has been
extensively used in the treatment of patients with type-2 diabetes.
Enhanced insulin action and decreased hepatic glucose output
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[6]. For the same degree of blood glucose reduction, metformin
treatment is associated with a lower risk of hypoglycaemia than
with insulin secretagogues and insulin treatment in patients with
type-2 diabetes [7,8]. Metformin also has a beneficial effect on the
risk of macrovascular complications in obese patients with type-2
diabetes [8].
Previous studies have demonstrated an insulin-sparing effect of
metformin treatment as an adjunct therapy to ongoing insulin
treatment in patients with type-1 diabetes. In contrast, the results
concerning glycaemic control and other metabolism-related
variables (e.g., body weight) are contradictory. Marked differences
between studies in baseline levels of glycaemic control (for
example, HbA1c ranged from 7.6% to 10.9%), relatively small
sample sizes and short duration of interventions (six months or less)
could contribute to such discrepancies [9–24]. Hence, the effect of
metformin treatment on glycaemic control and other cardiovas-
cular risk factors in patients with type-1 diabetes remains a matter
of controversy. We hypothesized that metformin treatment might
reduce glycaemia as well as other non-glycaemic cardiovascular
risk markers in patients with type-1 diabetes and persistent poor
glycaemic control. Here, we report the results of a one-year trial of
metformin versus placebo as an adjunct therapy in 100 patients
with type-1 diabetes and persistent poor glycaemic control.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1, Protocol
S1, Protocol S2, Amendment S1.
Study design
The study was an investigator-initiated, single-centre, random-
ized, double-masked, parallel trial of metformin versus placebo
treatments.
Participants
Inclusion, exclusion and withdrawal criteria are presented in
Table 1. The data were collected at Steno Diabetes Center,
Gentofte, Denmark.
Ethics
At the screening visit (21 month) patients gave written
informed consent. The study was conducted in accordance with
the Declaration of Helsinki and was approved by the Ethics
Committee of Copenhagen County, Denmark.
Interventions
Patients continued ongoing insulin therapy as well as their usual
outpatient clinical care throughout the study period (i.e.,
outpatient clinic visits were planned independently of patients’
participation in the study). Adjustments in life-style, home-
monitored blood glucose measurements, insulin dose and
concomitant medications were made at the discretion of the
patients and the clinicians in the outpatient clinic. After the
screening visit, patients entered a one-month run-in period, during
which they began a single-masked treatment with one placebo
tablet per day. Patients with a level of HbA1c$8.0% at the end of
the run-in period were randomized to continue ongoing insulin
therapy plus either metformin or placebo tablets for 12 months.
The dose of metformin or placebo was gradually increased by
forced titration once weekly (the starting dose of metformin was
500 mg once daily) reaching the maximum dose (1 g twice daily,
i.e., 2 g total daily dose) after three weeks. Doses were reduced if
adverse events occurred that could possibly have been associated
with the study medication. Once free of adverse events, the drug
dose was increased again and, if adverse events recurred, the lower
dose was resumed. Otherwise, through four regular scheduled
telephone consultations (at one and three months post-random-
ization and hereafter approximately every third to fourth month)
the study nurse ensured adequate study medication dose titration.
Active and placebo tablets were identical in appearance, taste and
smell. The near-maximum dose of metformin was chosen since
previous dose-response studies showed only slight additional
lowering of blood glucose and a tendency for more side effects
with higher doses of metformin [25]. Patients were advised to take
tablets just before or during their morning and evening meals.
Objectives
The objective of the trial was to assess the efficacy and safety of
adjunct metformin treatment during one year in adult patients
with type-1 diabetes and persistent poor glycaemic control.
Outcomes
Primary outcome. The level of HbA1c after 12 months
intervention.
Secondary outcomes. Pre-specified secondary outcomes
were additional variables related to glycaemic control (fasting
plasma glucose, insulin dose, body-weight, waist- and hip-
circumferences and adverse events including hypoglycaemia).
Safety variables included blood concentrations of haemoglobin,
creatinine, sodium, potassium, bicarbonate, cobalamin, folate,
Table 1. Inclusion, exclusion and withdrawal criteria
Inclusion criteria:
N Type-1 diabetes mellitus according to the World Health Organization 1999
definition
a, including age at onset of diabetes #35 years and a non-fasting
b
serum C-peptide #300 pmol/l.
N Diabetes duration$5.0 years.
N Age at enrolment$18.0 years.
N Mean HbA1c$8.5% including all available measurements during one year
before enrolment and HbA1c$8.5% at enrolment.
Exclusion and withdrawal criteria:
N HbA1c,8.0% at baseline (0-month study visit).
N Hypoglycaemic unawareness.
N Clinical signs of heart failure.
N Plasma creatinine above the normal upper limit.
N Plasma AST elevated more than three-fold above the normal upper limit.
N Factor II VII X decreased,0.7.
N Serious co-morbidities.
N Pregnancy.
N History of drug or alcohol abuse.
N Unexpected serious adverse events with potential relation to the study drug.
aSee reference [33].
bAt enrolment, the level of C-peptide was determined in non-fasting samples. In
the case of non-fasting C-peptide levels$300 pmol/l, a fasting sample and/or a
glucagon-stimulated C-peptide measure was obtained to evaluate beta cell
function. According to local guidelines, suggested cut-off levels for C-peptide
indicative of type-1 diabetes were: Fasting,300 pmol/l; after 1 mg i.v.
glucagon: #600 pmol/l.
Abbreviations:
HbA1c: HaemeglobinA1c
AST: Aspartate aminotransferase
doi:10.1371/journal.pone.0003363.t001
Metformin in T1DM Patients
PLoS ONE | www.plosone.org 2 October 2008 | Volume 3 | Issue 10 | e3363alkaline phosphatase, aspartate aminotransferase as well as
platelets and white blood cell counts. Compliance with the study
medication. Endpoints were assessed at enrolment (screening visit:
21-month visit), in the week before randomization (baseline, 0-
month visit) and on the last treatment day (end of treatment: 12-
month visit). Patients were asked to report immediately important
medical occurrences. Otherwise, through the four telephone
consultations (see above), the study nurse collected intermediate
information about insulin doses and adverse events, including
hypoglycaemia. Information about type and dose of concomitant
medications was collected at each of the three study visits
(screening, baseline and end of treatment).
Ancillary outcomes. The change in HbA1c during the run-in
period. Intermediate HbA1c measurements collected from visits in
the outpatient clinic between baseline and end of treatment visits.
Insulin doses at the three months telephone consultations. The
number of outpatient clinic visits during follow-up.
Unconsciousness during hypoglycaemic events. Self-reported
blood/plasma glucose levels during hypoglycaemic events.
Sample size. The study aimed to show the superiority of
metformin over placebo to influence the level of HbA1c and was
designed with a statistical power of 80% to detect a 0.60%
absolute HbA1c difference. This value was equal to the difference
reported between the conventional and metformin-treated groups
in the UK Prospective Diabetes Study [8]. There was an estimated
standard deviation (SD) of 1.0% for a two-sided 5% significance
level. Accordingly, 100 enrolled subjects were needed if up to ten
drop-outs were to occur.
Randomization–Sequence generation. Randomization was
performed using a pre-established computer-generated sequence in
blocks of three and four, with the block size masked during the trial.
Patients were stratified into four groups according to the baseline
level of HbA1c (# or .9.5%) and BMI (, or $25 kg/m
2).
Randomization–Allocation concealment. Double-masked
treatments were allocated using numbered drug containers.
Concealed treatment allocation was by central randomization
(by email correspondence). KLIFO A/S (Copenhagen, Denmark)
secured masking during the trial. A sealed copy of the
randomization sequence was available at the investigation site in
case of need for emergency unblinding.
Randomization–Implementation. KLIFO A/S established
the sequence. The trial clinicians enrolled patients. A person
unconnected with the study assigned participants to their groups.
Blinding. Treatment allocation was masked for participants,
clinicians and those evaluating outcomes until after database lock.
After close-out the code was two-step encrypted (first step: treatment
A or B; second step: A=metformin and B=placebo). The success of
the masking was assessed by patients and clinicians estimating
allocated treatments at end of treatment (without knowledge of the
treatment actually allocated or the other’s answer).
Blood sampling
At baseline and 12 month study visits, blood samples were
drawn in the fasting state. At enrolment, blood was collected as
random, non-fasting samples.
Biochemical and other analyses
HbA1c was measured by the ion-exchange HPLC-method
traceable to The Diabetes Control and Complication Trial
standard (Tosoh Bioscience, Minato, Japan; normal limits: 4.1–
6.4%; intra/inter assay SD of 0.04/0.10, respectively). HbA1c was
measured twice on each study visit and the mean of the
measurements of the two separately drawn blood samples was
used in all statistical analyses (mean [SD] absolute intra-subject
difference between HbA1c measurements, in percentage points,
baseline: 0.11% [0.11]; end of treatment: 0.14% [0.12];
corresponding to a mean [SD] intra-subject difference relative to
the mean of the two measurements, baseline: 0.6% [0.6%]; end of
treatment: 0.7% [0.6%]). Serum C-peptide was measured with
time-resolved fluoroimmunoassay (AutoDELFIA, PerkinElmer,
MA, USA; lower limit of detection: 10 pmol/l). Office arterial
blood pressure was assessed with a UA-779 automatic digital device
(A&D Instruments LTD., Abingdon, Oxon, UK), taking one
measurement on each arm after a minimum of 5 min at rest, seated
upright. The mean of the two measurements was analyzed. Safety
variables were measured using routine procedures at the Steno
Diabetes Center. Body weight and height as well as waist and hip
circumference were measured with the patient standing upright
wearing only underwear. Body mass index (BMI) was calculated as
body weight/height
2 (kg/m
2). At study visits, plasma glucose was
measured with the glucose-oxidase biosensor method (Medisense
Precision Xtra
TM hand-device, ABBOTT Laboritories, Bedford,
MA 017301, USA). At the periodical recordings (i.e., at telephone
contactsand atscheduledstudyvisits) patientswereasked to estimate
the average level of home-monitored blood/plasma glucose
measurements during hypoglycaemic events. Otherwise, home-
monitored blood/plasma glucose measurements were not captured
during the study. At enrolment, patients were asked to choose from
one or more of five categories of reasons for having unsatisfactory
glycaemic control: fear of hypoglycaemia; non-compliance with diet;
insufficient physical activity; technical difficulties, for example, with
insulin injections; other reasons.
Adverse events
Information about adverse events was collected with a
standardised questionnaire. A serious adverse event (SAE) was
defined as one fulfilling any of the following criteria: any untoward
medical occurrence that at any dose: resulted in death; was life-
threatening, required inpatient hospitalisation or prolongation of
existing hospitalisation; resulted in persistent or significant
disability/incapacity or was a congenital anomaly or birth defect.
Minor episodes of hypoglycaemia were considered to be those in
which the hypoglycaemic symptoms were treated by the patient;
major hypoglycaemic episodes were considered to be those in
which the condition induced loss of consciousness or when third-
party intervention was required to obtain treatment. Events of
unconsciousness during major hypoglycaemia were captured using
a separate category for this in the case-report form.
Compliance
Compliance and drug exposure during the study were assessed
by tablet counting. Compliance with the tablet consumption
schedule was calculated as the actual study drug consumption as a
percentage of the expected consumption according to the
currently prescribed study drug dose. Study drug exposure was
calculated as the actual consumption averaged over the total
number of days between the first and last study visits in the
treatment periods. The number of outpatient clinic visits was
estimated by the number of HbA1c measurements between (i.e.,
excluding) study visits.
Statistical methods
Subject characteristics. At enrolment, normally distributed
variables were compared using unpaired t-tests, whereas non-
normally distributed variables were analyzed with the Mann-
Whitney test. Categorical data were analyzed using Fisher’s exact
test or, in case of more than two categories, by Pearsons chi-square
test.
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treatment effects between the randomized interventions were
evaluated by comparison between end of treatment and baseline
levels (i.e., ‘‘change from baseline’’). An analysis of covariance
(ANCOVA) model was developed with treatment type (metformin
or placebo) as the fixed effect and baseline level as the covariate.
Primary outcome, secondary analyses. Further pre-
specified analyses of the primary outcome, HbA1c,i n c l u d e d
adjustment for the current (i.e., baseline and on-treatment) insulin
dose as well as interaction analyses of subgroups. The following
subgroups of patients were analyzed: (A) Substantial changes in the
insulinregimensduring thetrial(i.e.,changes ofinsulinpreparations,
for example, switching from human insulin to insulin analogues, or
vice versa [metformin: n=8, placebo: n=8], changes in the number
and/or the site of daily insulin injections of one or more insulin
preparations [metformin: n=3; placebo: n=6], or changes in
insulin preparations as well the number/site of injections
[metformin: n=1; placebo: n=3]). (B) Patients according to
dichotomized baseline levels of BMI (, or $25 kg/m
2), median
baseline levels of HbA1c (# or .9.15%) or of total daily insulin dose
(, or $0.72 U/kg). The dichotomization of BMI, HbA1c and
insulin dose was done since these patient characteristics have been
proposed as markers of insulin resistance–a suggested target of
metformin treatment. Hence, any interaction of treatment by
subgroups of patients according to the dichotomized baseline levels
of these variables could potentially discriminate responders to non-
responders of metformin therapy.
Secondary outcomes, primary analysis. Continuous
variables were analyzed using the baseline adjusted ANCOVA
model as for the primary outcome. Compliance as well as the
number of SAE’s were analyzed with the Mann-Whitney test.
Categorical data were analyzed using Fisher’s exact test.
Ancillary analyses. The HbA1c measurements were
investigated during the run-in period with adjustment for HbA1c
at enrolment. Due to the observed differences in lipid-lowering
therapies at enrolment/baseline, that is, statin and fish-oil therapies,
additional adjustment for these differences were performed for the
primary outcome, HbA1c. All follow-up (i.e., intermediate from
outpatient clinic visits as well as end of treatment) HbA1c
measurements at least one month post-randomization (a total of
354 HbA1c measurements) were evaluated in a repeated measures
analysis (mixed model with fixed effects: baseline HbA1c, treatment,
time and time by treatment interaction; random effects: subject and
subject by time interaction; covariance structure: variance
components) [26]. Subsequently, the first and the last available of
thesefollow-upHbA1cdataaswellasinsulindoseafterthreemonths,
were analyzed as for the primary outcome.
In addition to hypoglycaemia being evaluated as a categorical
variable (i.e., the number of patients reporting events), the number
of events was evaluated as a continuous variable (i.e., the number
of hypoglycaemic events was considered equidistant). Absolute
numbers of hypoglycaemic events during follow-up as well as
changes from enrolment or the run-period were evaluated. The
number of hypoglycaemic events and outpatient clinic visits during
follow-up (i.e., the number of HbA1c measurements) as well as the
self-reported blood/plasma glucose levels during hypoglycaemic
events were analyzed with the Mann-Whitney test (for compar-
isons between subjects) or the Wilcoxon signed rank test (for
comparisons within subjects). Categorical data were analyzed as
for the secondary outcomes.
Data for primary, secondary and ancillary outcomes are
summarised either as means (SD) for normally distributed
variables or as medians and ranges for non-normally distributed
variables. Treatment effects estimated by the model are presented
as means and associated 95% confidence intervals. In the
ANCOVA model, variables showed normally distributed residu-
als. No corrections for multiple testing were performed.
Statistical analyses were done with SPSS, version 14.0 (Chicago,
Illinois, USA).
Protocol deviations (with relation to the follow-up of
patients). In addition to the ancillary analyses as outlined, the
following patient related protocol deviations were noted (see
supplementary files Protocol S1 and S2 as well as Amendment S1
for details). Three screen-failure patients were included in the
analyses. One patient being diagnosed with diabetes after the age of
35 years. The patient fulfilled all other inclusion criteria (the patient
was 37 years old at diagnosis of diabetes and had a level of non-
fasting C-peptide ,10 pmol/l). At enrolment, the second screen-
failure patient presented with HbA1c of 8.30% (both measurements)
and, due to diabetic nephropathy, elevated plasma creatinine of 117
pmol/l (reference range: 62–100 mmol/l). In this patient, the
creatinine level normalized during the run-in period and all other
inclusion criteria were fulfilled (mean HbA1c was 9.7% during
the year before enrolment and, at randomization, the patient
presented with HbA1c measurements of 8.7% and 8.6%,
respectively). The third screen-failure patient presented with
increased levels of creatinine due to diabetic nephropathy (at
enrolment plasma creatinine was 120 mmol/l; at randomization
plasma creatinine was 105 mmol/l; referencerange: 62–100 mmol/l).
At enrolment, a total of five more patients presented with levels of
either creatinine (n=1) or factor II VII X (n=4) outside the
reference ranges, but in whom these variables normalized during the
run-in period. Due to adverse gastrointestinal events during the run-
in period (i.e., during single-masked placebo treatment), one patient
(in themetformingroup)wasunmaskedtothattreatment(i.e.,run-in
placebo).Otherwise no preterm unmasking occurred.One patientin
the placebo group, who experienced a SAE with potential relation to
the study drug (i.e., ketoacidosis precipitated by gastroenteritis–see
below) was not withdrawn from the study (one more patient, in the
placebo group, who experienced a SAE due to ketoacidosis–see
below–dropped out while hospitalized herefore).
Results
Subjects
All potentially eligible patients with type-1 diabetes at the Steno
Diabetes Center (n=459) were invited to participate. 111 patients
accepted (24%). Eleven patients were excluded before randomi-
zation. Thus, a total of 100 patients were randomized for the study
medication, of which 49 began treatment with metformin and 51
received placebo. Two patients [4.1%] were excluded during
metformin treatment and six patients [11.8%] dropped out from
the placebo group. Thus, 47 and 45 patients [95.9% and 88.2%]
completed the 12-month treatment period with metformin or
placebo, respectively (Figure 1).
Recruitment. Patients were enrolled from August 2004
through June 2005 and follow-up ended August 2006.
Subject characteristics
Among those invited patients who declined (n=348), approx-
imately half were male compared to approximately two-thirds of
those patients who accepted and performed the screening visit
(n=111) (p=0.037). Otherwise, at time of approach, age, known
duration of diabetes and the level of HbA1c were not significantly
different between the two groups (data not shown).
The clinical characteristics of study subjects at enrolment
(n=100) are summarized in Table 2. All patients were
Caucasians, and about two-thirds of them were male. Their mean
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diabetes of 25 to 30 years and a mean BMI of approximately 26
kg/m
2. Most patients received four daily insulin injections, thereby
receiving a daily dose of approximately 60 units. For the year
before and at enrolment, HbA1c was 9.5 to 9.6%. Non-compliance
with diet was the most frequently reported cause of persistent
unsatisfactory glycaemic control. Very few patients reported major
hypoglycaemic events within the preceding year. Except for
greater numbers of patients who received ongoing statin or fish-
oil therapies in the metformin group (p=0.039 and p=0.007,
respectively), the randomization procedure produced treatment
groups that were well matched for metabolic and clinical
characteristics (Table 2). Six patients or fewer within each non-
study medication category, as listed in Table 2, started and/or
stopped this medication during the trial.
Among excluded patients, mean HbA1c at screening was 8.93%
in the metformin group (n=2) and 10.04% in the placebo group
(n=6).
Figure 1. Patient flow scheme.
doi:10.1371/journal.pone.0003363.g001
Metformin in T1DM Patients
PLoS ONE | www.plosone.org 5 October 2008 | Volume 3 | Issue 10 | e3363Table 2. Subject characteristics at enrolment (21 month) for 100 patients with type-1 diabetes.
Subject characteristics Allocated metformin (n=49) Allocated placebo (n=51) p-value
Gender (men/women) 33 [67]/16 [33] 31 [61]/20 [39] 0.537
Age (years) 46.1 (11.6) 44.9 (10.8) 0.592
Known duration of diabetes (years) 30 (5; 51) 26 (6; 56) 0.775
Body weight (kg) 80.5 (12.5) 79.0 (15.3) 0.600
Height (m) 1.75 (0.10) 1.75 (0.09) 0.735
Body mass index (kg/m
2) 26.2 (3.4) 25.8 (4.3) 0.642
HaemoglobinA1c (%) 9.48 (0.99) 9.60 (0.86) 0.498
HaemoglobinA1c during the year before enrolment (%) 9.62 (0.83) 9.63 (0.67) 0.947
Non-fasting serum C-peptide (pmol/l) ,10 (,10; 188) ,10 (,10; 226) 0.712
Office systolic blood pressure (mmHg) 137.4 (18.2) 140.1 (17.4) 0.449
Office diastolic blood pressure (mmHg) 78.9 (11.4) 81.1 (9.9) 0.312
Heart rate (beats/minute) 76.7 (13.6) 75.4 (12.1) 0.605
Smoking (no/former/yes, daily or occasional) 19 [39]/11 [22]/19 [39] 26 [51]/7 [14]/18 [35] 0.374
Alcohol (drinks per day: none/1-3/.3)
a 13 [50]/13 [50]/0 [0] 14 [52]/13 [48]/0 [0] 2
b
Late diabetic complications:
Retinopathy (none/simplex/proliferative) 4 [8]/25 [51]/20 [41] 6 [12]/24 [47]/21 [41] 0.817
Macroangiopathy (no/yes)
c 39 [80]/10 [20] 45 [88]/6 [12] 0.283
Nephropathy (normo-/micro-/macroalbuminuria)
d 31 [63]/11 [22]/7 [14] 29 [57]/16 [31]/6 [12] 0.598
Neuropathy (no/yes)
e 25 [51]/24 [49] 28 [55]/23 [45] 0.841
Pre-study insulin therapy and hypoglycaemia:
Total daily insulin dose (Units)/(Units/kg) 59.8/0.74 (23.4/0.26) 59.1/0.75 (19.2/0.22) 0.866
No. of daily insulin injections (,4 daily/4 daily)
f 5 [10]/44 [90] 8 [16]/43 [84] 0.555
Minor hypoglycaemia (No. of events during the last month) 5 (0; 20) 4 (0; 20) 0.505
Major hypoglycaemia (No. of events during the last year) 0 (0; 3) 0 (0; 10) 0.756
Reported reasons for inadequate glycaemic control:
To avoid hypoglycaemia 16 [33] 15 [29] 0.830
Non-compliance with diet 23 [47] 24 [47] 2
b
Insufficient physical activity 15 [31] 19 [37] 0.531
Difficulties with insulin injections 5 [10] 5 [10] 2
b
Other reasons 19 [39] 23 [45] 0.549
Ongoing non-study medication:
Total on antihypertensive medication 30 [61] 28 [55] 0.549
ACE inhibitors or angiotensin II receptor blockers 28 [57] 24 [47] 0.326
Aldosterone antagonists 0 [0] 0 [0] 2
Thiazide or loop diuretics
g 17 [35] 15 [29] 0.669
Beta blockers 4 [8] 3 [6] 0.712
Calcium channel blockers 6 [12] 9 [18] 0.578
Other antihypertensive medication 0 [0] 0 [0] 2
Total on lipid-lowering medication 26 [53] 15 [29] 0.025
Statins
g 23 [47] 14 [27] 0.062
Fibrates 0 [0] 0 [0] 2
Fish oil 9 [18] 1 [2] 0.007
Other lipid-lowering medication 0 [0] 0 [0] 2
Other:
Aspirin 18 [37] 15 [29] 0.525
Non-steroid anti-inflammatory drugs 3 [6] 3 [6] 2
Dietary supplementations
g, h 4 [8] 1 [2] 0.200
Cobalamin supplementations 0 [0] 1 [2] 2
b
Folic acid supplementations 0 [0] 0 [0] 2
Potassium supplementations
g 14 [29] 12 [24] 0.651
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the primary outcome was analyzed as intention-to-treat: all
randomized patients exposed to the study medication with
HbA1c data available after a minimum of three months
treatment (metformin: n=48; placebo: n=50). The intention-to-
treat analysis included last observation carried forward (LOCF) for
missing values at end of treatment.
Numbers analyzed, secondary outcomes. The secondary
outcomes were analyzed similarly as for the primary outcome, that
is, including LOCF after three months post-randomization. Data on
insulin doses were available from study visits and intermediate
telephone contacts and were therefore evaluated in 48 and 50
patientsinthemetforminandplacebogroups,respectively.Forother
secondary outcomes, except for one drop-out patient (in the
metformin group) having available data for LOCF, only patients
who completed the study could be analyzed. Thus, other secondary
outcomes were evaluated in a maximum of 48 and 45 patients in the
metformin and placebo groups, respectively. During the trial, the
routine method for measuring levelsof folate was changed. Thus, for
serum folate, only patients with baseline and end of treatment
samples measured with identical such methods were evaluated
(metformin: n=29; placebo: n=26). Otherwise, the screening and
safety variables, reporting of adverse events and compliance were
evaluated in all randomized patients exposed to the randomized
study drugs (metformin n=49; placebo: n=51).
Numbers analyzed, ancillary outcomes. Except for the
repeated measures HbA1c analysis (see below), all analyses were
performed as for the primary outcome (i.e., intention-to-treat).
Follow-up HbA1c data were available for a total of 99 patients
(metformin: n=48; placebo: n=51) evaluated in the repeated
measures HbA1c analysis. Data from the analysis of the first and
the last available HbA1c is only shown for the subgroup of 72
patients (metformin: n=35; placebo: n=37) having available
HbA1c data from one to four months post-randomization.
Primary outcome, primary analysis
After 12 months, the between-treatments difference in HbA1c of
0.13% (20.19; 0.44) was not significant (p=0.422). In fact, the
drop in HbA1c (i.e., the change from baseline) was only significant
in the placebo group by approximately 0.2% (Table 3).
Primary outcome, secondary analyses
Adjustment for changes in total daily insulin dose did not
change the conclusions for HbA1c. Also, for HbA1c, interactions by
study drug treatment were not significant in subgroups of patients
categorised by baseline levels of BMI, median baseline levels of
HbA1c, total daily insulin dose, or by evidence of substantial
changes in the insulin regimen during the trial (data not shown).
Secondary outcomes, primary analysis
Levels of fasting plasma glucose showed approximately similar
patterns to those for HbA1c (Table 3). In contrast, after one year,
significant differences were observed between the metformin and
placebo groups of 25.7 units (28.6; 22.9) in total daily insulin
dose (p,0.001), of 21.74 kg (23.32; 20.17) in body weight
(p=0.030) and of 22.90 cm (25.03; 20.77) in hip circumference
(p=0.008). The changes in waist circumference and waist/hip
ratio were not significantly different between treatments (Table 3).
Adverse events and safety variables
The number of patients reporting minor or major episodes of
hypoglycaemia was not significantly different between treatments
(Table 4).
More patients reported a metallic taste in their mouth with the
metformin than with the placebo treatment (metformin: n=7;
placebo: n=1; p=0.029). Otherwise, no significant differences in
the number of patients reporting new-onset gastrointestinal
symptoms were observed between treatments either as separate
symptoms (data not shown) or as any new-onset gastrointestinal
symptom (metformin: n=43; placebo: n=39; p=0.310).
Cardiovascular symptoms, infections and other complaints were
infrequent and did not differ between treatment groups (data not
shown). One non-hypoglycaemia-related SAE in each of six patients
in the metformin group and 17 non-hypoglycaemia-related SAE’s in
11 patients in the placebo group were recorded. These proportions
of patients did not differ significantly between treatment groups
(Table 5). Before unmasking, no non-hypoglycaemia-related SAE
was considered potentially to have been associated with the study
medication in the metformin group, whereas two such SAE’s in the
placebo group (two cases of diabetic ketoacidosis precipitated by
Table 2. cont.
Subject characteristics Allocated metformin (n=49) Allocated placebo (n=51) p-value
Thyroxine 3 [6] 6 [12] 0.488
Data represent number of patients [%], mean (standard deviation) or median (range).
aInformation about daily alcohol intake was missing in 23 and 24 patients allocated metformin and placebo, respectively. The percentage of patients refers to those for
whom data were available.
bNot compared statistically due to equal proportions of patients or too few patients in treatment groups.
cPrevious ischaemic heart disease, stroke, transient ischaemic attack or peripheral arterial disease.
dNormo-, micro- and macro-albuminuria: 24-hour urinary albumin-excretion#29 mg, 30–299 mg and $300 mg, respectively, in two out of three consecutive samples.
One patient, in the metformin group, had a kidney transplant five years prior to enrolment due to polycystic kidney disease. The patient presented with normal levels
of creatinine and microalbuminura. Due to having prior kidney disease, the patient is included in the macroalbuminuria group.
eSymptomatic peripheral or autonomic neuropathy or clinical signs thereof.
fOne patient, in the metformin group, received continuous subcutaneous insulin-infusions. The patient is included in the group with four daily injections.
gDuring the run-in period, in the metformin group, one patient changed from thiazid to loop diuretics, one patient initiated statin treatment and two patients initiated
dietary (n=1) or potassium (n=1) supplementations, respectively, whereas, in the placebo group, one patient was temporarily treated with non-steroid anti-
inflammatory drugs. Thus, at baseline (0 months), in the metformin and placebo groups, respectively, a total of 24 (49%) and 14 (27%) patients received ongoing statin
treatment (p=0.039 between treatments); five (10%) and one (2%) patients received dietary supplementations (p=0.108 between treatments) and 15 (31%) and 12
(24%) patients received potassium supplementations (p=0.502 between treatments). In contrast, for the whole group of thiazid or loop diuretics as well as for non-
steroid anti-inflammatory drugs, despite changes herein during the run-in period, a similar number of patients received such treatments at baseline compared to
enrolment. Otherwise, patients did not start and/or stop other non-study medications as listed during the run-in period.
hOver-the-counter vitamin pills with unspecified cobalamin and folic acid content.
Abbreviation: ACE: Angiotensin converting enzyme.
doi:10.1371/journal.pone.0003363.t002
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or placebo.
Baseline
Metformin
Baseline
Placebo
EOT
Metformin EOT Placebo DMetformin DPlacebo
DMetformin
versus DPlacebo p-value
Subjects (number) 49 51 48 50 48 50 98
HaemoglobinA1c (%) 9.34 (0.92) 9.35 (0.69) 9.25 (0.94) 9.12 (0.86) 20.10
(20.32; 0.12)
20.23
(20.45; 20.01)
0.13
(20.19; 0.44)
0.422
Fasting plasma glucose (mmol/l) 11.01 (4.59) 13.30 (5.62) 12.11 (4.60) 11.72 (4.37) 0.04
(21.24; 1.32)
20.89
(22.21; 0.43)
0.93
(20.93; 2.79)
0.324
Total daily insulin dose (Units) 59.7 (25.5) 58.1 (17.9) 56.8 (24.3) 60.9 (20.0) 23.2
(25.2 21.2)
2.5 (0.6; 4.5) 25.7
(28.6; 22.9)
,0.001
Total daily insulin dose (Units/kg) 0.74 (0.29) 0.74 (0.20) 0.71 (0.25) 0.77 (0.24) 20.03
(20.06 20.01)
0.03
(20.01; 0.06)
20.06
(20.10; 20.02)
0.003
Body weight (kg) 80.23 (12.73) 78.98 (14.98) 78.78 (12.70) 79.16 (16.63) 21.21
(22.31; 20.12)
0.53
(20.60; 1.66)
21.74
(23.32; 20.17)
0.030
Body mass index (kg/m
2) 26.11 (3.55) 25.78 (4.16) 25.61 (3.39) 25.85 (4.87) 20.37
(20.72; 20.02)
0.19
(20.18; 0.55)
20.56
(21.06; 20.05)
0.031
Waist circumference (cm) 93.29 (10.44) 93.40 (12.10) 92.58 (10.46) 93.30 (12.88) 20.26
(21.68; 1.15)
20.06
(21.55; 1.44)
20.21
(22.27; 1.86)
0.843
Hip circumference (cm) 100.31 (7.19) 99.64 (10.32) 98.44 (7.07) 100.41 (10.62) 21.39
(22.86; 0.07)
1.51
(20.04; 3.05)
22.90
(25.03; 20.77)
0.008
Waist/Hip ratio 0.93 (0.08) 0.94 (0.07) 0.94 (0.08) 0.93 (0.07) 0.01
(20.01; 0.03)
20.01
(20.03; 0.01)
0.02
(20.00; 0.05)
0.100
Data at baseline (0 month) and EOT (12 months) are raw absolute values given as mean (standard deviation). Data for DMetformin and DPlacebo represent the mean
(95% confidence interval) estimated changes from baseline as predicted by the statistical model. The numbers of patients represent the maximum number of patients
included in each analysis. Data are presented as intention-to-treat including last observation carried forward.
Abbreviations:
EOT: End of treatment.
doi:10.1371/journal.pone.0003363.t003
Table 4. Reported hypoglycaemic episodes in patients with type-1 diabetes during one year of treatment with metformin or
placebo.
Metformin (n=49) Placebo (n=50) p-value
Minor hypoglycaemia:
Total number of patients with events (%) 48 (98.0) 49 (98.0) 2
a
Total number of events during follow-up 5391 4752 0.359
Number of events per subject month of follow-up, median (range) 9.0 (0.0; 29.9)
b 6.4 (0.0; 22.4)
b 0.312
Levels of plasma or blood glucose during events
c 2.87 (0.42) 3.01 (0.58) 0.238
Major hypoglycaemia:
Total number of patients with events (%) 15 (30.6) 10 (20.0) 0.254
Total number of events during follow-up 58 29 0.261
Number of events per subject year of follow-up, median (range) 0.0 (0.0; 10.8)
d 0.0 (0.0; 7.0)
d 0.259
Levels of plasma or blood glucose during events
c 1.96 (0.50) 2.06 (0.54) 0.508
Unconsciousness during events:
Total number of patients with events (%)
g 6 (12.2) 1 (2.0) 0.059
Total number of events during follow-up 10 2 ,0.05
e
Number of events per subject year of follow-up, median (range) 0.0 (0.0; 3.0) 0.0 (0.0; 1.7) 0.048
Levels of plasma or blood glucose during events
c 1.78 (0.30) 1.00 (2) 0.180
Data are included for at total of 99 patients (one patient, in the placebo group, out of a total of 100 randomized patients, had missing data on hypoglycaemia).
aNot compared statistically due to equal proportions of patients in treatment groups.
bp,0.05 compared to enrolment (Table 2).
cLevels of circulating glucose were captured periodically by patients estimating average levels of blood/plasma glucose during hypoglycaemic events. The calibration
(plasma or whole blood glucose) of hand held devices was not registrated, nor was devices calibrated at enrolment. Hence, data represent non-standardized plasma
and/or blood glucose measurements. Not all patients had available glucose measurements during events. The total number of patients with available measurement
was: Minor hypoglycaemia: metformin: n=47; placebo: n=49; Major hypoglycaemia: metformin: n=11; placebo: n=8.
dp=0.011 and p=0.209 compared to enrolment for metformin and placebo, respectively (Table 2).
ep=0.049888455.
doi:10.1371/journal.pone.0003363.t004
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ered to be potentially related to the study medication. No cases of
lactic acidosis occurred.
Levels of cobalamin and alkaline phosphatase decreased,
whereas levels of plasma potassium increased significantly in the
metformin group relative to the placebo group (mean [95%
confidence intervals] difference metformin versus placebo in
cobalamin: 283.3 pmol/l [2139.3; 227.3]; p=0.004; alkaline
phosphatase: 25.91 units/l [210.77; 21.05]; p=0.018; potassi-
um: 0.20 mmol/l [0.02; 0.38]; p=0.029). Levels of folate,
haemoglobin, aspartate aminotransferase, sodium, creatinine and
bicarbonate, as well as platelet and white blood cell counts did not
significantly differ between treatments (data not shown). At end of
treatment, in the metformin group, only one patient had levels of
plasma potassium above 5.5 mmol/l (the patient had plasma
potassium levels of 5.1 and 5.6 mmol/l before and after metformin
treatment, respectively) not requiring treatment. The case of
myocardial infarction and diabetic ketoacidosis, in the placebo
group, also showed hyperkalaemia (potassium 7.7 mmol/l).
Otherwise, no treatment of hyperkalaemia was necessary.
Compliance and study drug dose
The median (range) compliance was 90.0% (33.0; 126.0) for the
metformin group [n=47] and 92.3% (42.5; 123.5) for the placebo
group [n=45] (p=0.879). Approximately the same proportion of
patients in these respective groups (34.7% [17/49] and 31.4%
[16/51], p=0.832) received a reduced study drug dose resulting in
a median (range) daily study drug exposure of 1680 mg (416;
1954) in the metformin group and 1642 mg (152; 1989) in the
placebo group (p=0.836). Allocated treatments were correctly
estimated at end of treatment by 57.4% (27/47) and 71.1% (32/
45) of patients (p=0.007) and by clinicians for 52.1% (25/48) and
64.4% (29/45) of patients in the metformin and placebo groups,
respectively (p=0.144).
Ancillary analyses, HbA1c
During the run-in period, HbA1c decreased in both treatment
arms from approximately 9.5% at enrolment to about 9.3% at
randomization (Tables 2 and 3), (p,0.05 compared to enrolment;
p=0.267 between treatment arms). Adjustment for the use of
lipid-lowering therapy at enrolment/baseline, that is, statin and/or
fish-oil therapies, did not change the conclusions for HbA1c (data
not shown). In the repeated measures HbA1c analysis, the
treatment by time interaction was significant (p=0.032). Accord-
ingly, after approximately three months, in the subgroup of 72
patients having available HbA1c data from one to four months
post-randomization, HbA1c and insulin dose was significantly
lowered with metformin compared to placebo with no significant
differences in HbA1c after 12 months (Table 6). Similar conclu-
sions were obtained for all patients (data not shown).
Ancillary analyses, other
As compared to enrolment, both treatments significantly
increased the number of minor hypoglycaemic events per month,
whereas the number of major hypoglycaemic events per year was
significantly increased in the metformin group only (Tables 2 and
4). Similar was observed when compared to the run-in period (data
not shown). However, the reported number of minor and overall
major hypoglycaemic events was not significantly different
between treatments, whereas unconsciousness during major
hypoglycaemic events was reported more frequently in the
metformin group (Table 4). Similar was observed for the change
in minor or overall major hypoglycaemic events versus enrolment
or versus the run-in period between treatments (data not shown).
The estimated average levels of blood/plasma glucose during
events seemed to be approximately 1 mmol/l lower during major
versus minor hypoglycaemia (not statistically tested) with no
significant difference between treatments (Table 4). As estimated
by the number of HbA1c measurements, no significant difference
between treatment groups was observed in the number of
outpatient clinic visits (median [range] number of outpatient
clinic visits per patient, in patients included in the intention-to-
treat analysis, between randomization and end of treatment,
metformin: 3 visits [0; 6]; placebo: 3 visits [0; 6], p=0.362).
Discussion
Primary outcome, primary analysis
In this randomized, double-masked, parallel study, 100 patients
with type-1 diabetes, preserved hypoglycaemic awareness and
persistent inadequate glycaemic control were treated for 12 months
with either metformin or placebo as an adjunct therapy to ongoing
insulin therapy. After one year, there was no significant difference in
the levels of HbA1c between the two groups.
Of the previous studies investigating metformin treatment in
patientswithtype-1diabetes,andreportingefficacydatawithrespect
to HbA1c [16–24], that of Meyer et al. featured the largest sample
and the longest intervention period (62 patients followed for six
months). Patients presented with only mildly elevated pre-study
levels of glycaemia (HbA1c at enrolment was approximately 7.6%)
and no significant glycaemic effect after metformin therapy was
reported [20]. In comparison, our present study population
presented with persistent and pronounced poor glycaemic control
(mean HbA1c at enrolment was approximately 9.5%). Thus, the two
most extended trials of metformin treatment in patients with type-1
diabetes, that is, the study by Meyer et al and our present study, do
not suggest any long-term glycaemic benefit of metformin therapy-
no matter the pre-treatment level of glycaemic control.
Primary outcome, secondary analyses
However, a number of studies have suggested improved
glycaemic levels with metformin treatment of patients with type-
Table 5. Non-hypoglycaemia-related serious adverse events
in 100 patients with type-1 diabetes allocated treatment with
metformin or placebo for one year.
Metformin
(n=49)
Placebo
(n=51)
Serious adverse event type; No. of
events [No. of patients with events]:
Psychiatric 0 [0] 1 [1]
Neurological 1 [1] 2 [2]
Cardiovascular 2 [2] 5 [4]
Gynaecological 0 [0] 1 [1]
Musculo-skeletal 1 [1] 2 [2]
Metabolic 0 [0] 2 [2]
Infections 1 [1] 2 [2]
Trauma 1 [1] 2 [1]
Maximum number of events per patient 13
Total number of events [No. of patients
with events]
6 [6] 17 [11]
a
ap=0.151 and p=0.287 between metformin versus placebo for the total
number of events and total number of patients with events, respectively.
doi:10.1371/journal.pone.0003363.t005
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duration (six months or less) and, in most cases, included specific
subsets of patients selected because they presented potential
glucometabolic disturbances, such as obesity [23] or insulin
resistance [18], for example in adolescents [19,21,22]. In our
study, we investigated adult patients with type-1 diabetes and poor
glycaemic control with or without other known glucometabolic
disturbances. Non-obese and overweight/obese patients were
included and stratified according to their BMI. Baseline levels of
HbA1c, insulin dose or BMI (i.e., suggested indices of glucometa-
bolic disturbances potentially related to insulin-action) did not
show statistical evidence of interaction on the glycaemic response
to the two treatments. Hence, in our study, baseline variables,
potentially related to insulin-action, did not seem to affect the
long-term glycaemic response to metformin treatment. In
agreement with most previous studies, we found significantly
lower total daily insulin doses after metformin therapy than with
the placebo group [9–13,16–18,20,22–24]. The unaffected
conclusions for HbA1c after adjustment for changes in insulin-
dose, suggest that other changes in, for example, life-style, could
have masked a glucose-lowering effect of metformin therapy. Also,
at similar glycaemic levels, the lower insulin-dose after metformin
therapy, suggests a glucose-lowering and/or insulin-sensitizing
effect of metformin therapy in patients with type-1 diabetes.
Secondary outcomes, primary analyses
Body weight and hip circumference decreased significantly
during metformin treatment relative to the placebo group. For
body weight, similar has been observed during metformin therapy
in obese and non-obese patients with type-2 diabetes [7,27]. By
contrast, except for one study [18], previous studies of patients
with type-1 diabetes have reported no significant change in body
weight after metformin therapy [17,19–23]. In the general
population, insulinaemia and adiposity have been demonstrated
to be independent predictors of cardiovascular disease [28–31].
Hence, our present findings of decreased levels of such
cardiovascular risk-markers (assuming total daily insulin-dose is a
marker of insulinaemia) might translate into an improved
cardiovascular outcome of metformin therapy in patients with
type-1 diabetes and persistent poor glycaemic control.
In agreement with most [11,20,21,23], but not all [22] previous
studies, we found no significant difference between treatments in
the incidence of minor or overall major hypoglycaemia. The
proportions of patients with any new-onset gastrointestinal
symptom were similar in the two treatment groups. Levels of
cobalamin (but not of folate) and alkaline phosphatase were
significantly lower and levels of plasma potassium was significantly
higher during metformin treatment than with placebo, although
this did not result in significant differences in the incidence of
symptomatic complaints or in levels of haemoglobin, platelets or
aspartate aminotransferase. No treatment of hyperkalaemia was
needed in the metformin group. Thus, overall, metformin
treatment was well tolerated in our study population. Compliance
was satisfactory ($90%) in both treatment groups.
Ancillary analyses, HbA1c
Previous shorter-term studies (six months duration or less)
proposed improved glycaemic control with metformin in patients
with type-1 diabetes [9,12–14,18,19,21–24]. In our present study,
the intermediate HbA1c data suggested a time dependent effect
including a transient lowering of HbA1c after approximately three
months in the metformin group. Hence, the discrepancies between
Table 6. Effect of metformin versus placebo on follow-up (intermediate and study visit) levels of HbA1c and insulin doses in 72
patients with type-1 diabetes during a one year period.
Baseline
Metformin
Baseline
Placebo
Follow-up
Metformin
Follow-up
Placebo DMetformin DPlacebo
DMetformin
versus DPlacebo p-value
Patients with available HbA1c data from
one to four months post-randomization:
Subjects (number) 35 37 35 37 35 37 72
HbA1c, first available (%)
a 9.34 (1.02) 9.32 (0.68) 8.70 (1.01) 9.18 (0.89) 20.64
(20.86; 20.41)
20.14
(20.36; 0.08)
20.50
(20.81; 20.19)
0.002
Time from randomization (days)
b 2273 (39; 119) 91 (32; 119) 22 2 0.632
HbA1c, last available (i.e., EOT) (%)
c 9.34 (1.02) 9.32 (0.68) 9.07 (0.91) 9.18 (0.79) 20.27
(20.52; 20.02)
20.15
(20.39; 0.10)
20.12
(20.48; 0.23)
0.494
Total daily insulin dose
(3 months)(Units)
d
62.9 (28.2) 55.7 (18.0) 60.0 (25.8) 56.1 (19.1) 22.7
(24.3 21.0)
0.0
(21.6; 1.7)
22.7
(25.0 20.3)
0.026
Follow-up HbA1c data were obtained from planned study visits as well as from intermediate non-study outpatient clinic visits during the intervention period. All HbA1c
measurements obtained at least one month post-randomization were evaluated. Data are shown for the subgroup of 72 patients having available follow-up HbA1c
measurements from one to four months post-randomization. Data at baseline (0 month) and follow-up are raw absolute values given as mean (standard deviation) or
median (range). Data for DMetformin and DPlacebo represent the mean (95% confidence interval) estimated changes from baseline as predicted by the statistical
model.
aThe first available follow-up HbA1c measurement (in the group of 72 patients presented here, all the ‘‘first available’’ HbA1c data were obtained at intermediate
outpatient clinic visits). Given change from baseline estimates (i.e., DMetformin, DPlacebo and DMetformin versus DPlacebo) represent data without adjustment for
time. Additional adjustment for time did not change conclusions substantially (data not shown).
bTime from randomization until the first available HbA1c measurement.
cThe last available follow-up HbA1c measurement (obtained from study visits or intermediate outpatient clinic visits, that is, equal to EOT levels including last
observation carried forward).
dTotal daily insulin dose represents the last reported dose at the intermediate telephone consultations within the first three months post-randomization. The total
insulin doses corrected for body weight (i.e. Units/kg) are not shown since data for body weight at the date of reporting insulin doses (i.e. at the intermediate
telephone consultations) were not available.
Abbreviations:
EOT: End of treatment.
HbA1c: HaemoglobinA1c.
doi:10.1371/journal.pone.0003363.t006
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rather than differences in baseline glycaemic control, obesity etc.
Ancillary analyses, other
More events of unconsciousness during hypoglycaemia were
reported in the metformin group. Hence, although we recruited
patients with preserved hypoglycaemic awareness and there was
no significant difference in the incidence of reporting minor or
overall major hypoglycaemia at enrolment or after one year,
major hypoglycaemic events were potentially more serious with
metformin than with placebo.
Strenghts
In our opinion, the primary strength of the present study,
besides being adequately powered, double-masked, randomized
and with a clinical relevant primary outcome (HbA1c), is the length
of the study (i.e., a one year treatment period). Such study
duration is sufficient to overcome short-term changes in glycaemic
control as well as to provide some evidence of potential longer-
term effects. Moreover, the selected study population, that is,
patients with longstanding poor glycaemic control, is important
since these patients have the poorest prognosis and they might
have shown glycaemic benefits from adjunct metformin treatment.
Also, the setting of the study (i.e., to a large extent in the outpatient
clinic) makes the results more relevant to the clinical practice
compared to studies using only highly motivated scientific
investigators for the follow-up of patients.
Limitations
Our present study has limitations. First, except for gender, the
clinical characteristics were not significantly different between
those patients who agreed to participate compared to those who
did not. After randomization, the proportions of men and women
were similar between treatment groups. We therefore do not
expect the recruitment process to substantially having affected the
outcomes. Second, except for lipid-lowering therapies (i.e., statin
and fish-oil therapies), at enrolment, treatment groups were well
matched for other known clinical characteristics. We do not
suspect the randomization procedure to have been inadequate and
therefore can assume these observed imbalances to have been
chance phenomena. Also, the similar conclusions for HbA1c after
adjustment for the differences in lipid-lowering therapies at
enrolment/baseline suggest that these imbalances did not impact
significantly on the glycaemic outcomes of the study. Third, we
selected adult patients with a history of poor glycaemic control.
Hence, although our findings agree with those of some shorter-
duration studies [11,16,17,20], we cannot rule out the possibility
that other categories of patients with type-1 diabetes, for example,
those with less severe glycaemic dysregulation, adolescents, overtly
obese people, etc., might experience glycaemic benefits of
metformin treatment during a follow-up of one year or more.
Fourth, insulin doses were adjusted at the discretion of the patients
and clinicians in the outpatient clinic. The adjustment for changes
in insulin doses did not seem to significantly influence the overall
result for HbA1c. Nevertheless, we cannot discount the possibility
that increased attention to minimize or prevent the lowering of
insulin doses would have lowered HbA1c by treatment with
metformin during one year. However, a treatment design aiming
for minimal adjustments of insulin doses, could increase the risk
and/or the severity of major hypoglycaemia (as suggested from our
data) and so compromises its ethical legitimacy. Also, the
interaction of changes in insulin treatment regimen and study
drug treatment was not significant, the number of outpatient clinic
visits did not differ significantly between treatment groups and
only six patients or fewer started or stopped other concomitant
medications during the study. Hence, except for potential lifestyle
changes as outlined, we do not expect potential unintended
differences occurring during the outpatient clinic follow-up to have
substantially affected the primary outcome. Fifth, the analyses of
intermediate HbA1c data were not pre-specified. Also, the timing
as well as the number of intermediate HbA1c measurements was
not standardized between patients. Hence, these data should be
interpreted extremely cautious (i.e., they could be chance findings
and hypothesis generating). Sixth, the estimated average blood/
plasma glucose levels during hypoglycaemic events were self-
reported and no calibration of blood/plasma glucose devices was
done. Hence, the estimates of the absolute blood/plasma glucose
levels during hypoglycaemic events were probably not accurate.
However, the observed tendency towards lower reported blood/
plasma glucose levels during major versus minor hypoglycaemia
(although not statistically tested) agreed with our clinical expectation.
Hence, we find it likely that these observed (potential) differences in
blood/plasma glucose levels adequately reflected the corresponding
differences in hypoglycaemic severity. Seventh, corrections for
multiple testing were not performed. If p-values had been corrected
according to the Bonferroni method, only total daily insulin-dose
would have remained significant different between treatments (data
not shown). However, the Bonferroni method, by nature, increases
the risk of type II statistical errors. In our opinion, rather issues
related to study-design as well as existing biological and clinical
knowledge should judge the issue of multiplicity [32]. Most
secondary and ancillary analyses were, as outlined, in agreement
with previously demonstrated effects of metformin treatment in
patients with type-1 or type-2 diabetes. We therefore do not expect
multiplicity as a main driving force for our findings.
Conclusions
In 100 patients with type-1 diabetes, preserved hypoglycaemic
awareness and persistent poor glycaemic control, we observed no
significant difference in glycaemic levels after one year in those
with an adjunct treatment of metformin or of placebo. After
one year, the incidence of overall hypoglycaemia was similar in
the two treatment groups. Metformin therapy was well-tolerated
and resulted in decreased total daily insulin doses, body-weight,
hip-circumference and serum cobalamin as well as a clinically
insignificant increase in plasma potassium. Hence, in our study
population, metformin therapy did not offer a simple solution to a
complex glucoregulatory problem. Further investigations into the
potential cardiovascular-protective effects of metformin therapy in
patients with type-1 diabetes are warranted.
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